Tratamiento de Primera Línea de la Dermatitis Atópica Cuando la Hidratación No Es Suficiente
Escenario Clínico
La dermatitis atópica que permanece sin control a pesar de la hidratación sola justifica la adición de farmacoterapia tópica activa. Este protocolo de primera línea define el siguiente paso basado en evidencia en esa situación.
Enfoque de Tratamiento — resumen parcial únicamente
El protocolo implica agregar una clase específica de agente tópico aplicado una vez al día, con restricciones definidas sobre qué tipos de agentes deben evitarse en sitios anatómicos sensibles o durante períodos de tratamiento prolongados.
Respuesta Esperada
Se espera típicamente una mejoría de la dermatitis atópica dentro de las 2 a 6 semanas de iniciar la terapia.
References
DOI: 10.1016/j.anai.2023.11.009
- In patients with uncontrolled atopic dermatitis refractory to moisturization alone, the JTF panel recommends addition of a topical corticosteroid over no topical corticosteroid (strong recommendation, high-certainty evidence).
- In patients aged 3 months or older with uncontrolled atopic dermatitis refractory to moisturization alone, the JTF panel recommends addition of a topical calcineurin inhibitor (pimecrolimus, tacrolimus) over no added topical calcineurin inhibitor (strong recommendation, high-certainty evidence).
- In patients with uncontrolled atopic dermatitis using mid-to high-potency topical treatments (tacrolimus, topical corticosteroid US classes 1-5), the JTF panel suggests applying the medication once per day over twice per day (conditional recommendation, moderate certainty evidence).
- Avoid high-potency (classes 1 and 2) TCS for prolonged periods of time (>4 weeks) and limit its use on sensitive areas (face, folds, groin)—rare instances of atrophy, telangiectasia, and striae may be more likely to occur in these areas.
- The available RCTs systematically reviewed (topical and systemic NMAs) and AD experts typically expect response to mid- or high-potency topical therapy within 2 to 6 weeks.
View source ↗